Is secukinumab (Cosentyx) an effective dual therapy for both psoriatic arthritis and hidradenitis suppurativa?

Secukinumab (Cosentyx) for Dual Treatment of Psoriatic Arthritis and Hidradenitis Suppurativa

Yes, secukinumab is an excellent choice for dual treatment when a patient has both psoriatic arthritis and hidradenitis suppurativa, as it is FDA-approved and guideline-recommended for both conditions with strong efficacy data.

FDA Approval Status

Secukinumab has explicit FDA approval for both conditions 1:

• Psoriatic arthritis (PsA): Approved for patients 2 years and older with active disease
• Hidradenitis suppurativa (HS): Approved for adults with moderate to severe disease

This dual indication makes secukinumab uniquely positioned as a single agent that can simultaneously address both inflammatory conditions.

Evidence for Psoriatic Arthritis

For PsA, secukinumab demonstrates robust efficacy with Level A recommendations 2:

• The 2019 AAD-NPF guidelines give secukinumab a Strength A recommendation for monotherapy in plaque psoriasis when associated with psoriatic arthritis 2
• The 2020 EULAR guidelines recommend IL-17 inhibitors (including secukinumab) when there is relevant skin involvement alongside peripheral arthritis 3
• The 2024 EULAR update specifically prioritizes IL-17A inhibitors for axial disease when skin involvement is present 4

Dosing for PsA: 300 mg subcutaneously at weeks 0,1,2,3, and 4, followed by 300 mg every 4 weeks 2. Recent data shows IV formulations are also effective 5.

The drug shows sustained efficacy through 52 weeks with excellent ACR50 response rates and demonstrates effectiveness across all PsA manifestations including peripheral arthritis, axial disease, enthesitis, and dactylitis 3, 4, 6.

Evidence for Hidradenitis Suppurativa

For HS, secukinumab has Level Ib evidence with demonstrated efficacy in phase 3 trials 7, 8:

The SUNSHINE and SUNRISE trials (2023) showed:

• Secukinumab 300 mg every 2 weeks achieved significantly higher HiSCR (Hidradenitis Suppurativa Clinical Response) rates compared to placebo at week 16
• SUNSHINE trial: 45% response rate vs 34% placebo (p=0.0070)
• SUNRISE trial: 42% response rate vs 31% placebo (p=0.015)
• Responses were sustained through week 52 and maintained through week 104 in extension studies 7, 8

Critical dosing difference for HS: The approved and effective regimen is 300 mg every 2 weeks (not every 4 weeks as used in PsA) 7, 9.

Real-world data confirms effectiveness with 75% of patients achieving HiSCR at 48 weeks, with significant improvements in quality of life and pain scores 9.

Practical Dual Treatment Algorithm

When treating both conditions simultaneously:

1. Use the HS dosing schedule: 300 mg subcutaneously every 2 weeks

   • This more frequent dosing adequately treats PsA while optimizing HS control
   • The every-4-week PsA dosing is insufficient for HS 7

2. Loading phase: Administer at weeks 0,1,2,3, and 4 (standard for both conditions)

3. Maintenance: Continue 300 mg every 2 weeks indefinitely for dual control

4. Monitor response:

   • For PsA: Assess at 12-16 weeks using disease activity measures (DAS28, ACR criteria)
   • For HS: Assess HiSCR at 16 weeks (≥50% reduction in abscess/nodule count with no increase in abscesses or draining fistulae)

5. Adjunctive measures for HS: Continue daily topical antiseptics on affected areas 7

Safety Considerations

The safety profile is consistent across both indications 10, 1:

Key monitoring requirements:

• Screen for tuberculosis before initiation
• Avoid in active infections
• Monitor for mucocutaneous candidiasis (typically mild and manageable)
• Caution with inflammatory bowel disease: New cases or exacerbations reported; discontinue if IBD develops 10, 1
• Neutropenia can occur but is usually mild and transient

Contraindications:

• Active tuberculosis infection
• Clinically important active infection
• Hypersensitivity to secukinumab

Advantages Over Alternative Biologics

Compared to TNF inhibitors:

• Secukinumab may be preferred when significant skin involvement is present 3, 4
• For HS specifically, adalimumab is the only other FDA-approved biologic, but secukinumab offers an alternative mechanism of action for TNF-inadequate responders

Compared to IL-12/23 inhibitors:

• Secukinumab (IL-17A inhibition) has stronger evidence for both PsA and HS compared to ustekinumab
• IL-23 inhibitors lack approval for HS

Common Pitfalls to Avoid

1. Do not use every-4-week dosing when treating concurrent HS—this will undertreated the hidradenitis suppurativa 7

2. Do not discontinue if only partial HS response at 16 weeks—many patients continue to improve through 52 weeks 7, 8

3. Do not overlook the need for adjunctive HS management—continue antiseptics, pain management, and consider surgical intervention for scarring/fistulae 11

4. Monitor for IBD symptoms carefully—this is a specific concern with IL-17 inhibition that requires vigilance 10, 1

Case Report Evidence

A published case demonstrates successful dual treatment: a 47-year-old woman with both HS and psoriasis achieved excellent outcomes for both conditions with secukinumab after failing multiple other therapies 12.

In summary, secukinumab at 300 mg every 2 weeks represents an evidence-based, FDA-approved, single-agent solution for patients with both psoriatic arthritis and hidradenitis suppurativa, with the critical caveat that the more frequent HS dosing schedule must be used to adequately treat both conditions.